[Cardiopulmonary effects of prostaglandin E1. Aspects of drug safety].
Heidrich
H
H
Franziskus-Krankenhaus, Berlin.
Breddin
H K
HK
Rudofsky
G
G
Scheffler
P
P
D000527:Alprostadil / Q000009:adverse effects* / Q000627:therapeutic use; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D011654:Pulmonary Edema / Q000139:chemically induced*; D012307:Risk Factors
D000527:Alprostadil
Kardiopulmonale Wirkungen von Prostaglandin E1. Aspekte zur Arzneimittelsicherheit.